ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years
Kenneth L Pitter
Matched on ORCID iD 0000-0002-9450-313X; OpenAlex author ID A5052753028; NIH RePORTER profile ID 10572480. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 1
- Labs led
- 1
- Collaborators
- 31
2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper, 1 grant
Papers 4
- Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognosis. Co-author DOI 10.1016/j.hpb.2025.08.015↗
- Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
- Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. Co-author DOI 10.1158/0008-5472.can-22-1742↗
- Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. First author DOI 10.1073/pnas.1920240117↗
Grants 1
Closest collaborators
The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Eric David Miller · 2 shared papers, 2024–2025 · strength 0.37
- Paper Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognos… DOI 10.1016/j.hpb.2025.08.015↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Ashish Manne · 2 shared papers, 2024–2025 · strength 0.37
- Paper Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognos… DOI 10.1016/j.hpb.2025.08.015↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Jordan M. Cloyd · 2 shared papers, 2024–2025 · strength 0.37
- Paper Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognos… DOI 10.1016/j.hpb.2025.08.015↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Mary E. Dillhoff · 2 shared papers, 2024–2025 · strength 0.37
- Paper Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognos… DOI 10.1016/j.hpb.2025.08.015↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Anne M. Noonan · 2 shared papers, 2024–2025 · strength 0.37
- Paper Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognos… DOI 10.1016/j.hpb.2025.08.015↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Shafia Rahman · 2 shared papers, 2024–2025 · strength 0.37
- Paper Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognos… DOI 10.1016/j.hpb.2025.08.015↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Matilda Holm · 2 shared papers, 2020–2022 · strength 0.22
- Paper Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. DOI 10.1158/0008-5472.can-22-1742↗
- Paper Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreati… DOI 10.1073/pnas.1920240117↗
- Olivera Grbovic-Huezo · 2 shared papers, 2020–2022 · strength 0.22
- Paper Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. DOI 10.1158/0008-5472.can-22-1742↗
- Paper Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreati… DOI 10.1073/pnas.1920240117↗
- Tuomas Tammela · 2 shared papers, 2020–2022 · strength 0.22
- Paper Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. DOI 10.1158/0008-5472.can-22-1742↗
- Paper Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreati… DOI 10.1073/pnas.1920240117↗
- Christine A. Iacobuzio–Donahue · 2 shared papers, 2020–2022 · strength 0.22
- Paper Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. DOI 10.1158/0008-5472.can-22-1742↗
- Paper Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreati… DOI 10.1073/pnas.1920240117↗
- Patrick W. Underwood · 1 shared paper, 2025 · strength 0.22
- Timothy Michael Pawlik · 1 shared paper, 2025 · strength 0.22
- Sameek Roychowdhury · 1 shared paper, 2024 · strength 0.15
- Davendra P. S. Sohal · 1 shared paper, 2024 · strength 0.15
- Upender Manne Manne · 1 shared paper, 2024 · strength 0.15
- Kannan Thanikachalam · 1 shared paper, 2024 · strength 0.15
- Ashwini Kumar Esnakula · 1 shared paper, 2024 · strength 0.15
- Wancai Yang · 1 shared paper, 2024 · strength 0.15
- Lianbo Yu · 1 shared paper, 2024 · strength 0.15
- Ankur Sheel · 1 shared paper, 2024 · strength 0.15
- Anup Kasi · 1 shared paper, 2024 · strength 0.15
- Aslam M. Ejaz · 1 shared paper, 2024 · strength 0.15
- Ravi Kumar Paluri · 1 shared paper, 2024 · strength 0.15
- Dana Pe'er · 1 shared paper, 2022 · strength 0.13
- Simon Joost · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.